When the last major wave of “blockbuster” psychiatric drugs such as Prozac arrived on the market in the late 1980s and 90s, they ushered in a new era in the treatment of depression. With fewer serious side effects than their predecessors and aggressively marketed as a new class of “wonder drug”, they were prescribed very quickly to tens of millions of people living with depression and other debilitating conditions worldwide while pharmaceutical companies made a fortune.
A quarter of a century later, questions are being asked about what, if anything, will be the next significant leap forward in psychiatric pharmacology, be it for depression or other diagnoses such as schizophrenia or anxiety. With a quarter of the population likely to experience some kind of mental health difficulty in their lifetime, it is a pretty important question. Read more…
rayalaseema360 